DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 6 A, 2010, Pages 1303-1317

  Bellail, Anita C ^a   Tse, Margaret C L ^a   Song, Jin H ^a   Phuphanich, Surasak ^b   Olson, Jeffrey J ^a   Sun, Shi Yong ^a   Hao, Chunhai ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Caspase 8; DR5; Glioblastoma; TRAIL

Indexed keywords

CASP8 PROTEIN, HUMAN; CASPASE 8; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEA15 PROTEIN, HUMAN; PHOSPHOPROTEIN; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK1 PROTEIN, HUMAN; SIGNAL PEPTIDE; TNFRSF10B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CELL MEMBRANE; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM; PATHOLOGY; PROTEIN TRANSPORT; TUMOR CELL LINE; DRUG EFFECTS;

APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CELL LINE, TUMOR; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE MICRODOMAINS; NF-KAPPA B; PHOSPHOPROTEINS; PROTEIN TRANSPORT; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77955165505     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00777.x     Document Type: Article

References (50)

1. Stupp R, Mason WP, van den Bent MJ. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352:987-96.
2. Lefranc F, Facchini V, Kiss R. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist. 2007, 12:1395-403.
3. Giese A, Bjerkvig R, Berens ME. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003, 21:1624-36.
4. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol. 2005, 23:2411-22.
5. Hao C, Beguinot F, Condorelli G. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res. 2001, 61:1162-70.
6. Song JH, Song DK, Pyrzynska B. TRAIL triggers apoptosis in malignant glioma cells through extrinsic and intrinsic pathways. Brain Pathol. 2003, 13:539-53.
7. Li YC, Tzeng CC, Song JH. Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy. Clin Cancer Res. 2006, 12:2716-29.
8. Smyth MJ, Takeda K, Hayakawa Y. Nature's TRAIL-on a path to cancer immunotherapy. Immunity. 2003, 18:1-6.
9. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 2003, 14:337-48.
10. Mariani SM, Krammer PH. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol. 1998, 28:973-82.
11. Jo M, Kim TH, Seol DW. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 2000, 6:564-7.
12. Lawrence D, Shahrokh Z, Marsters S. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med. 2001, 7:383-5.
13. Hao C, Song JH, Hsi B. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res. 2004, 64:8502-6.
14. Gajewski TF. On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol. 2007, 25:1305-7.
15. Xiao C, Yang BF, Asadi N. Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem. 2002, 277:25020-5.
16. Song JH, Tse MCL, Bellail A. Lipid rafts and non-rafts mediate TRAIL-induced apoptotic and non-apoptotic signals in non-small cell lung carcinoma cells. Cancer Res. 2007, 67:1-10.
17. Clancy L, Mruk K, Archer K. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci U S A. 2005, 102:18099-104.
18. Wagner KW, Punnoose EA, Januario T. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med. 2007, 13:1070-7.
19. Sheikh MS, Huang Y, Fernandez-Salas EA. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene. 1999, 18:4153-9.
20. Liu X, Yue P, Khur FR. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res. 2005, 65:9169-75.
21. Merino D, Lalaoui N, Morizot A. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006, 26:7046-55.
22. Scaffidi C, Medema JP, Krammer PH. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J Biol Chem. 1997, 272:26953-8.
23. Medema JP, Scaffidi C, Kischkel FC. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 1997, 16:2794-804.
24. Yang X, Chang HY, Baltimore D. Autoproteolytic activation of pro-caspases by oligomerization. Mol Cell. 1998, 1:319-25.
25. Hao C, Song JH, Vilimanovich U. Modulation of TRAIL signaling complex. Vitam Horm. 2004, 67:81-99.
26. Chaudhary PM, Eby M, Jasmin A. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity. 1997, 7:821-30.
27. Irmler M, Thome M, Hahne M. Inhibition of death receptor signals by cellular FLIP. Nature. 1997, 388:190-5.
28. Condorelli G, Vigliotta G, Iavarone C. PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus. EMBO J. 1998, 17:3858-66.
29. Kataoka T, Tschopp J. N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-kappaB signaling pathway. Mol Cell Biol. 2004, 24:2627-36.
30. Krueger J, Chou FL, Glading A. Phosphorylation of phosphoprotein enriched in astrocytes (PEA-15) regulates extracellular signal-regulated kinase-dependent transcription and cell proliferation. Mol Biol Cell. 2005, 16:3552-61.
31. Hao C, Parney IF, Roa WH. Cytokine and cytokine receptor mRNA expression in human glioblastomas: evidence of Th1, Th2 and Th3 cytokine dysregulation. Acta Neuropathol. 2002, 103:171-8.
32. Tu S, McStay GP, Boucher LM. In situ trapping of activated initiator caspases reveals a role for caspase-2 in heat shock-induced apoptosis. Nat Cell Biol. 2006, 8:72-7.
33. Lassar AB, Davis RL, Wright WE. Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell. 1991, 66:305-15.
34. Schuck S, Honsho M, Ekroos K. Resistance of cell membranes to different detergents. Proc Natl Acad Sci U S A. 2003, 100:5795-800.
35. Eckert A, Bock BC, Tagscherer KE. The PEA-15/PED protein protects glioblastoma cells from glucose deprivation-induced apoptosis via the ERK/MAP kinase pathway. Oncogene. 2008, 27:1155-66.
36. Tinel A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science. 2004, 304:843-6.
37. La Ferla-Bruhl K, Westhoff MA, Karl S. NF-kappaB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition. Oncogene. 2007, 26:571-82.
38. Hehner SP, Heinrich M, Bork PM. Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem. 1998, 273:1288-97.
39. Micheau O, Lens S, Gaide O. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol. 2001, 21:5299-305.
40. Bodmer JL, Holler N, Reynard S. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol. 2000, 2:241-3.
41. Varfolomeev E, Maecker H, Sharp D. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem. 2005, 280:40599-608.
42. MacFarlane M, Inoue S, Kohlhaas SL. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ. 2005, 12:773-82.
43. Kelley RF, Totpal K, Lindstrom SH. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem. 2005, 280:2205-12.
44. Kurbanov BM, Fecker LF, Geilen CC. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene. 2007, 26:3364-77.
45. Lin Y, Devin A, Cook A. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of I-kappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol. 2000, 20:6638-45.
46. Harper N, Farrow SN, Kaptein A. Modulation of tumor necrosis factor apoptosis-inducing ligand-induced NF-kappa B activation by inhibition of apical caspases. J Biol Chem. 2001, 276:34743-52.
47. Trauzold A, Siegmund D, Schniewind B. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene. 2006, 25:7434-9.
48. Muppidi JR, Siegel RM. Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nat Immunol. 2004, 5:182-9.
49. Legler DF, Micheau O, Doucey MA. Recruitment of TNF receptor 1 to lipid rafts is essential for TNF-alpha-mediated NF-kappaB activation. Immunity. 2003, 18:655-64.
50. Doan JE, Windmiller DA, Riches DW. Differential regulation of TNF-R1 signaling: lipid raft dependency of p42mapk/erk2 activation, but not NF-kappaB activation. J Immunol. 2004, 172:7654-60.